Homology Medicines Inc (NASDAQ:FIXX) has earned an average recommendation of “Buy” from the eight ratings firms that are presently covering the company, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $33.00.
A number of equities research analysts have recently weighed in on FIXX shares. ValuEngine raised Homology Medicines from a “hold” rating to a “buy” rating in a report on Saturday, October 19th. Oppenheimer started coverage on Homology Medicines in a report on Friday, November 1st. They set a “market perform” rating on the stock. Robert W. Baird assumed coverage on Homology Medicines in a report on Monday, September 9th. They set an “outperform” rating and a $30.00 price target on the stock. HC Wainwright set a $36.00 target price on Homology Medicines and gave the stock a “buy” rating in a report on Tuesday, September 24th. Finally, Canaccord Genuity set a $37.00 target price on Homology Medicines and gave the stock a “buy” rating in a report on Friday, July 26th.
NASDAQ:FIXX traded down $0.44 during mid-day trading on Wednesday, hitting $11.45. The company had a trading volume of 171,000 shares, compared to its average volume of 236,728. The business has a fifty day simple moving average of $15.07 and a 200-day simple moving average of $18.53. The firm has a market capitalization of $544.30 million, a price-to-earnings ratio of -5.73 and a beta of -0.01. Homology Medicines has a 1 year low of $11.26 and a 1 year high of $31.80.
Homology Medicines (NASDAQ:FIXX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.61) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.06). The business had revenue of $0.39 million for the quarter, compared to the consensus estimate of $1.00 million. Homology Medicines had a negative net margin of 3,232.67% and a negative return on equity of 38.74%. As a group, sell-side analysts forecast that Homology Medicines will post -2.39 EPS for the current year.
In related news, insider Albert Seymour sold 9,300 shares of the business’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $17.39, for a total transaction of $161,727.00. Also, CFO W Bradford Smith sold 6,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $18.74, for a total value of $112,440.00. Following the sale, the chief financial officer now directly owns 6,000 shares in the company, valued at approximately $112,440. The disclosure for this sale can be found here. In the last three months, insiders have sold 56,766 shares of company stock worth $1,027,914. 33.40% of the stock is owned by corporate insiders.
Large investors have recently made changes to their positions in the stock. Aperio Group LLC bought a new stake in Homology Medicines during the second quarter worth approximately $34,000. Bank of Montreal Can bought a new position in shares of Homology Medicines in the second quarter valued at $40,000. Cubist Systematic Strategies LLC bought a new position in shares of Homology Medicines in the second quarter valued at $42,000. Marshall Wace LLP bought a new position in shares of Homology Medicines in the first quarter valued at $74,000. Finally, Royal Bank of Canada increased its holdings in shares of Homology Medicines by 300.0% in the second quarter. Royal Bank of Canada now owns 4,000 shares of the company’s stock valued at $78,000 after buying an additional 3,000 shares in the last quarter. 68.07% of the stock is currently owned by hedge funds and other institutional investors.
About Homology Medicines
Homology Medicines, Inc, a genetic medicines company, focuses on translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases. Its proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a range of genetic disorders.
Further Reading: FAANG Stocks
Receive News & Ratings for Homology Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Homology Medicines and related companies with MarketBeat.com's FREE daily email newsletter.